With Rare Speed, Gene Editing Emerges as Biotech’s New Cutting Edge

The Nobel Prize got Wall Street’s attention. On Oct. 7, the Swedish Academy awarded 2020’s Nobel in chemistry to two scientists for the development of Crispr-Cas9—a molecular scissors that can find and edit almost any sequence in a cell’s DNA. The 2012 discovery by Emmanuelle Charpentier and Jennifer Doudna had been commercialized with rare speed, and the Nobel was a boost for three companies founded to develop Crispr gene-editing therapies: Crispr Therapeutics,Intellia Therapeutics,and Editas Medicine.The three gene-editing stocks have more than doubled in the past few months, reaching a total market value above $23 billion.